Related Experiment Videos
[The midterm evolution in the percutaneous closure of ductus arteriosus with the Rashkind prosthesis]
J I Zabala Argüelles1, J García Fernández, J L Zunzunegui Martínez
1Departamento de Pediatría, Hospital General Universitario Gregorio Marañón, Madrid.
Anales Espanoles De Pediatria
|April 1, 1996
Summary
Percutaneous patent ductus arteriosus (PDA) occlusion using a Rashkind device is a safe and effective alternative to surgery for all age groups. This minimally invasive procedure achieved high occlusion rates, even in infants, with good long-term outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pediatric Cardiology
Background:
- Percutaneous patent ductus arteriosus (PDA) occlusion is an alternative to surgical closure.
- This study evaluated the safety and efficacy of percutaneous PDA occlusion in different age groups.
Purpose of the Study:
- To assess the outcomes of percutaneous PDA occlusion using Rashkind devices.
- To compare results between pediatric patients younger than 18 months (Group I) and older patients (Group II).
Main Methods:
- 44 patients underwent percutaneous PDA occlusion between April 1990 and July 1994.
- Patients were divided into two groups based on age: Group I (<18 months) and Group II (>18 months).
- Color Doppler was used to assess residual shunt; device embolization and removal were documented.
Main Results:
- Overall occlusion rates were 75% (Group I) and 64.5% (Group II) immediately after implantation.
- At 6 months, occlusion rates improved to 83% (Group I) and 84% (Group II).
- After a second device implantation, occlusion rates reached 100% (Group I) and 97% (Group II) with minimal residual shunt.
Conclusions:
- Percutaneous PDA occlusion with Rashkind devices is a valid therapeutic option for all age groups.
- The procedure demonstrated high success rates and acceptable complication profiles.
- This technique offers a viable alternative to surgical closure for patent ductus arteriosus.